Skip to content

Topical rapamycin in facial angiofibroma

Topical rapamycin in the treatment of facial angiofibroma - FA

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/08/020503
Enrollment
5
Registered
2019-08-01
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: Q851- Tuberous sclerosis

Interventions

Intervention1: Rapamycin gel/ointment: Rapamycin (sirolimus) is a lipophilic macrocyclic lactone which was first isolated from a soil bacterium Streptomyces hygroscopicus in Rapa Nui (Easter Island) i

Sponsors

MGM Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All patients of facial angiofibroma

Exclusion criteria

Exclusion criteria: Pregnancy, severe illness

Design outcomes

Primary

MeasureTime frame
Rapamycin (sirolimus) is a lipophilic macrocyclic lactone. It is used after renal transplantation and is routinely incorporated in drug-eluting stents during cardiac angioplasty. Rapamycin is very poorly water soluble, severely limiting its bioavailability. Currently it is available in the market in two formulations: Rapamycin oral solution and Rapamycin tablet. Effectiveness is measured by Facial Angiofibroma Severity Index (FASI).Timepoint: Patients will be followed up every 2 weeks and investigations will be done every month.

Secondary

MeasureTime frame
There may be treatment related complications e.g erythema, itching, irritation.Timepoint: Topical rapamycin will be discontinued and patient will be started on topical steroid till resolution of complications.

Countries

India

Contacts

Public ContactDr A D Gulanikar

MGM Medical College and Hospital, Aurangabd

agulanikar@hotmail.com9822377963

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026